PT  - JOURNAL ARTICLE
AU  - Padeniya, Padmapani
AU  - Ediriweera, Dileepa
AU  - De Silva, Arjuna
AU  - Niriella, Madunil
AU  - Premawardhena, Anuja
TI  - Using FIB-4 score as a screening tool in the assessment of significant liver fibrosis (F2) in patients with transfusion dependent beta thalassaemia: a cross sectional study
AID  - 10.1101/2022.01.15.22269369
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.01.15.22269369
4099  - http://medrxiv.org/content/early/2022/01/16/2022.01.15.22269369.short
4100  - http://medrxiv.org/content/early/2022/01/16/2022.01.15.22269369.full
AB  - Objective To evaluated the performance of FIB-4 score as a screening tool to detect significant liver fibrosis (F2) compared to transient elastography (TE), among chronic transfusion-dependent beta-thalassemia (TDT) patients, in a resource-poor setting.Design A cross-sectional studySetting Adolescent and Adult Thalassaemia Care Center (University Medical Unit), Kiribathgoda, Sri Lanka.Participants 45 TDT patients who have undergone more than 100 blood transfusions with elevated serum ferritin >2000ng/mL, were selected for the study. Patients who were serologically positive for hepatitis C antibody were excluded.Outcome measures TE and FIB-4 score were estimated at the time of recruitment in all participants. Pre-defined cut-off values for F2, extracted from previous studies for TE and FIB-4 score, were compared. A new cut-off value for FIB-4 score was estimated using ROC curve analysis to improve the sensitivity for F2 prediction.Results Of the selected 45 TDT patients, 22(49%) were males. FIB-4 score showed a significant linear correlation with TE (r= 0.52;p< 0.0003). The FIB-4 score was improbable to lead to a false classification of TDT patients to have F2 when the FIB-4 cut-off value was 1.3. On the other hand, it had a very low diagnostic yield in missing almost all (except one) of those who had F2. Using a much-lowered cut-off point of 0.32 for FIB-4, we improved the pick-up rate of F2 to 72%.Conclusions Regardless of the cut-off point, FIB-4 score cannot be used as a good screening tool to pick-up F2 in patients with TDT, irrespective of their splenectomy status. On the contrary, at 1.3 cut off value though FIB-4 is a very poor detector for F2 fibrosis it will not erroneously diagnose F2 fibrosis in those who don’t have it.Strengths and limitations of this studyThere is limited information available on the applicability of FIB-4 score to assess significant liver fibrosis in patients with transfusion-dependent beta-thalassemia (TDT).The present study among a Sri Lankan TDT population had their liver fibrosis assessed by FIB-4 score biomarker compared with Transient elastography (TE).Small sample size of the study is one of the major limitations.Even though the liver biopsy is the gold standard method of assessing liver fibrosis, non-invasive TE was used as the reference standard in our studyCompeting Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by a grant from the University Grant Commission, Colombo, Sri Lanka. The grant was awarded under the scheme of Financial assistance for higher studies for university teachers and was granted to carry out a PhD.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical clearance was obtained from the Ethics Review Committee (ERC) of the Faculty of Medicine, University of Kelaniya, Sri Lanka and the study was performed in accordance with the declaration of Helsinki.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors